Photo of Lauren Fincher

Lauren Fincher

Subscribe to Lauren Fincher's Posts

Lauren has vast experience handling state attorneys general investigations, navigating complex regulatory compliance matters, and providing strategic counsel in enforcement actions across various industries. She helps clients manage high-stakes regulatory matters and guides them through complex legal landscapes.

Contact:Read more about Lauren Fincher

Troutman Pepper Locke State Attorneys General (AG) team members Lauren Fincher, Michael LaFleur, and Bill LaRosa will speak at a BARBRI CLE on Tuesday, June 9 from 1–2:30 p.m. ET. The program, “Challenging State Civil Investigative Demands Prohibited by Federal Law: Strategies and Practical Tips,” will address strategies and best practices for litigators responding to state AG civil investigative demands (CIDs) and investigative subpoenas, including an introduction to state AG CIDs, response options, and common pitfalls. The panel will also discuss the Supreme Court’s unanimous decision in First Choice Women’s Resource Center v. Platkin, _ U.S. _ (2026), and offer approaches tailored to industries frequently targeted by state AG investigations.

In this episode of our special 12 Days of Regulatory Insights podcast series, RISE Practice Group Partners Lauren Fincher and Brian O’Reilly look at practical, recent developments and trends in open records laws for 2025. They explore the diverse — and often competing — perspectives in the public records space: protecting sensitive business information submitted to government versus fulfilling disclosure obligations as a governmental body.

In this episode of our special 12 Days of Regulatory Insights podcast series, Chris Carlson, a partner in our RISE practice group and member of the State Attorney General (AG) team, is joined by colleagues Lauren Fincher, also a partner in our RISE practice and State AG team, and Barry Boise, a partner in our Health Care + Life Sciences Litigation practice, to examine how state AGs approached the health care sector in 2025, and what’s coming next in 2026.

What Happened:

A unanimous panel of the U.S. Court of Appeals for the Fourth Circuit revived a suit against certain pharmaceutical distributors brought under West Virginia public nuisance law. The panel held that the effects of over-distributing prescription opioids may constitute a public nuisance under West Virginia law, defined distributors’ duties under the Controlled Substances Act (CSA), and held that abatement may include monetary funding to remediate alleged community harm. Notably, the Fourth Circuit’s decision comes after the West Virginia Supreme Court declined to determine the scope of West Virginia public nuisance law, and as a result, the decision refused to limit the scope of public nuisance law without guidance from the West Virginia Supreme Court.